Victoria Mazoteras-Pardo
◽
Ricardo Becerro-De-Bengoa-Vallejo
◽
Marta Elena Losa-Iglesias
◽
Daniel López-López
◽
David Rodríguez-Sanz
◽
...
Background
Hypertension is considered as a main risk factor for chronic kidney disease development and progression. Thus, the control and evaluation of this disease with new software and devices are especially important in patients who suffer from chronic kidney disease.
Objective
This study aimed to validate the QardioArm mobile device, which is used for blood pressure (BP) self-measurement in patients who suffer from chronic kidney disease, by following the European Society of Hypertension International Protocol 2 (ESH-IP2) guidelines.
Methods
A validation study was carried out by following the ESH-IP2 guidelines. A sample of 33 patients with chronic kidney disease self-measured their BP by using the QardioArm and Omron M3 Intellisense devices. Heart rate (HR), diastolic BP, and systolic BP were measured.
Results
The QardioArm fulfilled the ESH-IP2 validation criteria in patients who suffered from chronic kidney disease.
Conclusions
Thus, this study is considered as the first validation using a wireless upper arm oscillometric device connected to an app to measure BP and HR meeting the ESH-IP2 requirements in patients who suffer from chronic kidney disease. New validation studies following the ESH-IP2 guidelines should be carried out using different BP devices in patients with specific diseases.
Validation of the Omron M3 Intellisense (HEM-7051-E) Upper Arm Blood Pressure Monitor, for Self-Measurement, according to the European Society of Hypertension International Protocol Revision 2010 in a Stage 3–5 Chronic Kidney Disease Population